Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2026
Framework for Statistical Parametric Mapping of the Interactions between Glioblastoma Location, Treatment, Prognostic Variables, and Survival Using a Phase III Trial.
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
purposeBrain tumor location is known to affect survival, but there is a lack of methodologic tools for systematically studying the complex interplay between brain tumor location, prognostic variables, treatment schemes, and survival. EXPERIMENTAL
designA total of 592 prospectively enrolled patients with newly diagnosed glioblastoma from the phase III AVAglio trial, randomized to postsurgical chemoradiation with or without bevacizumab, were retrospectively analyzed. Statistical parametric mapping was conducted with multivariate Cox proportional hazards models at the voxel-wise level, incorporating dedicated interaction variables to evaluate the impact of baseline tumor volume and treatment arm on survival for different tumor locations from magnetic resonance imaging (MRI) scans, with subsequent cluster-based correction for multiple testing and mathematical estimation of regional survival curves.
resultsTumor location in the right prefrontal cortex was an independent favorable prognostic factor [median hazard ratio (HR) = 0.57] for survival, whereas tumor involvement in left hemisphere eloquent areas with language and visual functions was unfavorable (median HR = 1.69). Larger presurgical tumor volumes were associated with shorter survival independent of tumor location (HR = 1.005), but the effect was larger for tumor locations including eloquent structures (HR ranging 1.008-1.015), whereas nonsignificant for anterior frontal locations. Bevacizumab seemed to grant a survival benefit when specific brain regions were involved or spared by the tumor, but this result was not confirmed after correction for multiple testing.
conclusionsThis workflow allows to map the survival effects of variables onto specific brain tumor locations, revealing location dependency of prognostic variables such as tumor volume, and potentially of treatment schemes, with relevant implications in risk stratification and clinical management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.